Advertisement

Document › Details
Freeline Therapeutics Ltd.. (11/14/18). "Press Release: Freeline Appoints Brian M. Silver as Chief Financial Officer and Head of Corporate Development".
![]() |
Region | New York, NY |
Country | United States (USA) | |
![]() |
Organisation | Freeline Therapeutics Ltd., NY Office |
Group | Freeline Therapeutics (Group) | |
![]() |
Product | gene therapy |
Product 2 | investment banking | |
![]() |
Person | Silver, Brian M. (Freeline Therapeutics 201811– CFO + Head CorpDev based in US before Perella Weinberg + Morgan Stanley) |
Person 2 | Prener, Anne (Freeline Therapeutics 201707– CEO before Gyroscope Therapeutics + Baxalta + Novo Nordisk) | |
Freeline is pleased to announce the appointment of Brian M. Silver as Chief Financial Officer and Head of Corporate Development. Brian will be based in New York, as the Company establishes offices in the United States.
Brian brings to Freeline 25 years of experience as an investment banker and corporate lawyer. He has for many years focused on the biopharmaceutical and pharmaceutical services sectors, advising clients on a range of transactions including mergers and acquisitions, joint ventures and licensing arrangements, and capital raises across the equity, debt, royalty and convertible securities markets.
Most recently, Brian was a Partner and Head of Biotechnology in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. Prior to that, Brian was a Managing Director in Morgan Stanley’s healthcare investment banking group and a corporate associate at Sullivan & Cromwell. He received a Bachelor of Arts with honours from Harvard College and a Juris Doctor with honours from the University of Chicago Law School.
Anne Prener, Chief Executive Officer of Freeline, said: "We are delighted to welcome Brian to the Freeline team. He has extensive experience in the investment banking sector that will help us achieve our company’s vision of becoming a leading gene therapy company. Brian’s expertise will be invaluable as we continue to expand our pipeline and our organisation with the aim of bringing life-changing gene therapies to patients."
Brian Silver, Chief Financial Officer and Head of Corporate Development of Freeline, commented: "I am excited to join the Freeline team at such a transformational stage in the company’s development. Freeline intends to build a leading global gene therapy company and I look forward to working with my new colleagues as we progress our programmes through the clinic and towards the market."
- Ends -
Further information
JW Communications
Julia Wilson
+44 (0) 7818 430877
juliawilsonuk@gmail.com
About Freeline
Freeline is a privately-held clinical-stage biotechnology company focused on AAV based gene therapy targeting the liver. Our vision is to create better lives for people suffering from chronic systemic diseases using the potential of gene therapy as a one-time curative treatment. Freeline is headquartered in the UK and has operations in Germany and the US.
Record changed: 2020-02-17 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for Freeline Therapeutics (Group)
- [1] Freeline Therapeutics Ltd.. (6/30/20). "Press Release: Freeline Closes $120 Million Series C Financing Round". London....
- [2] Freeline Therapeutics Ltd.. (5/4/20). "Press Release: Freeline Receives Orphan Drug Designation from the FDA for FLT190 for the Treatment of Fabry Disease". London....
- [3] Freeline Therapeutics Ltd.. (2/12/20). "Press Release: Freeline Presents Data on Its AAV-based Gene Therapies for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium". London....
- [4] Freeline Therapeutics Ltd.. (2/4/20). "Press Release: Freeline Appoints Theresa Heggie as Chief Executive". London....
- [5] Freeline Therapeutics Ltd.. (19/12/19). "Press Release: Syncona Makes a Further $80 Million Commitment to Freeline". London....
- [6] Freeline Therapeutics Ltd.. (6/13/19). "Press Release: Freeline Announces Senior Leadership Transition and Completion of Series B Financing Milestones"....
- [7] Freeline Therapeutics Ltd.. (6/19/18). "Press Release: Freeline Secures Over £88 Million of Funding". London....
- [8] Freeline Therapeutics Ltd.. (7/10/17). "Press Release: Freeline Therapeutics Appoints Anne Prener as Chief Executive Officer"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
» top